CN104394882B - 成纤维细胞生长因子21蛋白 - Google Patents

成纤维细胞生长因子21蛋白 Download PDF

Info

Publication number
CN104394882B
CN104394882B CN201380030788.4A CN201380030788A CN104394882B CN 104394882 B CN104394882 B CN 104394882B CN 201380030788 A CN201380030788 A CN 201380030788A CN 104394882 B CN104394882 B CN 104394882B
Authority
CN
China
Prior art keywords
homodimer
seq
fgf21
protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380030788.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104394882A (zh
Inventor
R·J·达林
C·D·迪金森
D·A·德赖弗
M·D·贡西亚茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104394882(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104394882A publication Critical patent/CN104394882A/zh
Application granted granted Critical
Publication of CN104394882B publication Critical patent/CN104394882B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380030788.4A 2012-06-11 2013-06-05 成纤维细胞生长因子21蛋白 Expired - Fee Related CN104394882B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261658104P 2012-06-11 2012-06-11
US61/658,104 2012-06-11
US201361777386P 2013-03-12 2013-03-12
US61/777,386 2013-03-12
PCT/US2013/044190 WO2013188181A1 (en) 2012-06-11 2013-06-05 Fibroblast growth factor 21 proteins

Publications (2)

Publication Number Publication Date
CN104394882A CN104394882A (zh) 2015-03-04
CN104394882B true CN104394882B (zh) 2016-06-22

Family

ID=48670814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030788.4A Expired - Fee Related CN104394882B (zh) 2012-06-11 2013-06-05 成纤维细胞生长因子21蛋白

Country Status (24)

Country Link
US (2) US8741841B2 (2)
EP (1) EP2858662B1 (2)
JP (1) JP6182600B2 (2)
KR (1) KR20150006060A (2)
CN (1) CN104394882B (2)
AR (1) AR091216A1 (2)
AU (1) AU2013274638A1 (2)
BR (1) BR112014029966A2 (2)
CA (1) CA2871145A1 (2)
CL (1) CL2014003078A1 (2)
CO (1) CO7151525A2 (2)
EA (1) EA201492053A1 (2)
EC (1) ECSP14030742A (2)
ES (1) ES2644787T3 (2)
HK (1) HK1203357A1 (2)
IL (1) IL235832A0 (2)
IN (1) IN2014MN02132A (2)
MX (1) MX2014015257A (2)
PE (1) PE20150201A1 (2)
PH (1) PH12014502766A1 (2)
SG (1) SG11201408095XA (2)
TN (1) TN2014000439A1 (2)
TW (1) TWI513705B (2)
WO (1) WO2013188181A1 (2)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
CA2871656A1 (en) * 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
EP3107937A4 (en) 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CA2943355C (en) 2014-03-25 2023-09-05 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (ja) * 2014-09-08 2018-04-11 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CN105348380B (zh) * 2015-12-28 2019-03-01 江苏康缘瑞翱生物医药科技有限公司 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
AU2017358289C1 (en) * 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
JP2022530216A (ja) * 2019-04-23 2022-06-28 エルジー・ケム・リミテッド 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118190A1 (en) * 2003-12-10 2009-05-07 John Michael Beals Muteins of fibroblast growth factor 21
CN102143758A (zh) * 2008-06-04 2011-08-03 安姆根有限公司 Fgf21突变体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CH699521A2 (de) 2008-09-09 2010-03-15 Rotorcraft Ag Streckwerk für eine Strickmaschine.
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118190A1 (en) * 2003-12-10 2009-05-07 John Michael Beals Muteins of fibroblast growth factor 21
CN102143758A (zh) * 2008-06-04 2011-08-03 安姆根有限公司 Fgf21突变体及其用途

Also Published As

Publication number Publication date
EA201492053A1 (ru) 2015-02-27
JP6182600B2 (ja) 2017-08-16
HK1203357A1 (en) 2015-10-30
CO7151525A2 (es) 2014-12-29
IL235832A0 (en) 2015-01-29
US8741841B2 (en) 2014-06-03
KR20150006060A (ko) 2015-01-15
CL2014003078A1 (es) 2015-02-27
BR112014029966A2 (pt) 2017-09-12
CN104394882A (zh) 2015-03-04
IN2014MN02132A (2) 2015-09-11
CA2871145A1 (en) 2013-12-19
AU2013274638A1 (en) 2014-11-06
SG11201408095XA (en) 2015-01-29
AR091216A1 (es) 2015-01-21
EP2858662B1 (en) 2017-08-09
MX2014015257A (es) 2015-03-05
TW201408693A (zh) 2014-03-01
US20140228282A1 (en) 2014-08-14
TN2014000439A1 (en) 2016-03-30
WO2013188181A1 (en) 2013-12-19
EP2858662A1 (en) 2015-04-15
US20130330336A1 (en) 2013-12-12
US8927492B2 (en) 2015-01-06
PE20150201A1 (es) 2015-02-19
ES2644787T3 (es) 2017-11-30
PH12014502766A1 (en) 2015-02-09
ECSP14030742A (es) 2015-09-30
JP2015527974A (ja) 2015-09-24
TWI513705B (zh) 2015-12-21

Similar Documents

Publication Publication Date Title
CN104394882B (zh) 成纤维细胞生长因子21蛋白
CN103906530B (zh) 成纤维细胞生长因子21变体
CN104364261B (zh) 成纤维细胞生长因子21变体
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
CN106459222A (zh) Mic‑1融合蛋白及其用途
WO2014149699A1 (en) Bifunctional protein
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
KR20220115975A (ko) 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
HK40061872B (zh) 胰岛素-fc融合蛋白及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160622

Termination date: 20190605

CF01 Termination of patent right due to non-payment of annual fee